Moderna reports fiscal Q4 2025 results: revenue $678.0M, down 30% from a year earlier

Moderna filed a Form 8-K with the SEC on Feb 13, 2026, 7:02 AM ET, reporting an event dated Feb 13, 2026. It covers Item 2.02 (Results of Operations and Financial Condition); Item 9.01 (Financial Statements and Exhibits). The results cover fiscal Q4 2025 (quarter ended Dec 31, 2025); figures below are from the company's XBRL financial data filed with the SEC.

• Revenue: $678.0M (−29.8% from $966.0M a year earlier) [derived from annual minus nine-month figures]
• Operating income: −$857.0M (vs −$1.25B a year earlier) [derived from annual minus nine-month figures]
• Net income: −$826.0M (vs −$1.12B a year earlier) [derived from annual minus nine-month figures]
• Diluted EPS: $-2.11 (vs $-2.91 a year earlier) [derived from annual minus nine-month figures]
• Form 8-K accepted by EDGAR Feb 13, 2026, 7:02 AM ET
• Accession number 0001682852-26-000015

SEC filing 8-K · accession 0001682852-26-000015 · sec.gov ↗